Globus Medical
$ 95.25
2.68%
17 Apr - close price
- Market Cap 12,882,854,000 USD
- Current Price $ 95.25
- High / Low $ 96.54 / 93.60
- Stock P/E 24.30
- Book Value 33.86
- EPS 3.92
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.12 %
- 52 Week High 101.40
- 52 Week Low 51.79
About
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Analyst Target Price
$110.08
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-04 | 2025-08-07 | 2025-05-08 | 2025-02-18 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 1.28 | 1.18 | 0.86 | 0.68 | 0.84 | 0.83 | 0.75 | 0.72 | 0.6 | 0.57 | 0.63 | 0.53 |
| Estimated EPS | 1.1536 | 0.77 | 0.75 | 0.74 | 0.7486 | 0.65 | 0.68 | 0.57 | 0.61 | 0.57 | 0.59 | 0.51 |
| Surprise | 0.1264 | 0.41 | 0.11 | -0.06 | 0.0914 | 0.18 | 0.07 | 0.15 | -0.01 | 0 | 0.04 | 0.02 |
| Surprise Percentage | 10.957% | 53.2468% | 14.6667% | -8.1081% | 12.2095% | 27.6923% | 10.2941% | 26.3158% | -1.6393% | 0% | 6.7797% | 3.9216% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GMED
2026-04-18 08:39:07
This article analyzes Globus Medical (GMED) using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio approaches to determine if its current share price of US$92.76 offers fair value. The DCF model suggests the stock is 13.1% overvalued, with an intrinsic value of $82.03 per share. While the P/E ratio of 23.33x is below industry and peer averages, it's slightly above Simply Wall St's proprietary "Fair Ratio," indicating it might be somewhat expensive.
2026-04-13 10:39:02
Globus Medical (GMED) recently received a Zacks Rank #1 (Strong Buy) upgrade due to increased analyst confidence and higher earnings estimates. This upgrade reinforces the company's earnings momentum while integration risks from acquisitions remain a key concern. The article highlights how this positive shift in analyst sentiment interacts with Globus Medical's existing investment narrative focused on robotics innovation and successful acquisition integration, with projected revenues of $3.6 billion and earnings of $624.6 million by 2029.
2026-04-10 14:40:18
This article analyzes Globus Medical (GMED) after its recent stock price run to determine if it's overvalued. Using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio analyses, it suggests the stock might be overvalued by 11.4% and slightly over its fair ratio, respectively. The article also presents different "Narratives" from analysts, offering both optimistic and cautious views on the company's future growth and valuation.
2026-04-05 00:39:35
This article assesses Globus Medical's (GMED) valuation following recent share price activity and its robotics growth narrative. While a narrative suggests GMED is 20.1% undervalued with a fair value of $110.08, based on robotics innovation and operational efficiencies, the market presents a mixed signal with a P/E ratio in line with its own fair value but below industry averages. Investors are prompted to consider if the opportunity lies in closing the gap to analyst targets or if sentiment could cool.
2026-03-31 23:39:04
Globus Medical (GMED) has experienced a recent share price pullback, declining 4.2% in 7 days and 12.5% in 30 days, though still showing positive long-term returns. According to a Discounted Cash Flow (DCF) analysis by Simply Wall St, GMED is considered fairly valued at US$84.55 per share against its current price of US$83.51. The company also appears undervalued based on its P/E ratio of 21.0x compared to an estimated Fair Ratio of 22.4x.
2026-03-26 22:41:45
The Vanguard Group filed an amended Schedule 13G/A for Globus Medical Inc., reporting 0% beneficial ownership after an internal realignment on January 12, 2026. This amendment clarifies that Vanguard's subsidiaries will now report their beneficial ownership separately in accordance with SEC Release No. 34-39538, rather than indicating a sale or purchase of GMED shares. Investors should look for future filings from Vanguard's subsidiaries for specific holdings.
